UNSPSC 51263149: Betaxolol hydrochloride

This classification denotes a beta-adrenergic blocking agent and anti-glaucoma agent with the molecular formula C18H29NO3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6X97D2XT0O, chemically known as 2-propanol, 1-(4-(2-(cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino)-, hydrochloride, (+-)- but more generally known as betaxolol hydrochloride, which bears US NIH Compound Identifier 107952.

UNSPSC 51263149 Betaxolol hydrochloride is a Commodity code that nominally covers a specific beta-blocker pharmaceutical, but the recent state and local opportunities posted under this code show little relevant activity aligned with betaxolol procurement itself. The single concrete solicitation on record—Seminole County, Florida's IFB60459723LAS—actually seeks naloxone and drug deactivation systems for community health delivery, which fall outside the betaxolol scope. The Texas Health and Human Services Commission RFI (HHS0017013) addresses direct-to-manufacturer prescription programs broadly, without specification of individual drug products. The code appears to capture pharmacy and pharmaceutical supply activities across state health agencies and county health departments, but the mismatch between the nominal scope and the actual work being bought suggests either tagging inconsistency or that betaxolol-specific procurement rarely moves through state and local channels at a volume sufficient to generate recent activity under this code.

Activity is limited to Florida and Texas so far. Seminole County's naloxone and deactivation-systems IFB (posted June 30, 2026, due July 26, 2023) calls for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the county's community health building in Sanford and fixed-fee pricing on a two-year initial term plus one-year renewal option. Texas HHS's April 2026 RFI explores vendor capability for direct-to-manufacturer prescription programs but does not quantify demand or commit to contract value. Neither opportunity explicitly targets betaxolol procurement. Given the sparse and misaligned recent record, the code warrants close monitoring but does not present a clear market signal for betaxolol-specific business development at this time.